📊 TMCI Key Takeaways
Is Treace Medical Concepts, Inc.. (TMCI) a Good Investment?
Treace Medical exhibits severe operational distress despite exceptional 79.8% gross margins, with net losses of -$59.0M worsening YoY and negative free cash flow of -$29.5M. The company is burning cash unsustainably with only $10.7M in reserves against $55.6M debt and a -10.2x interest coverage ratio, creating imminent solvency risk.
Why Buy Treace Medical Concepts, Inc.. Stock? TMCI Key Strengths
- Excellent gross margin of 79.8% indicating strong product demand and pricing power
- Stagnant but not declining revenue at 1.6% YoY growth
- Reasonable leverage ratio of 0.64x Debt/Equity providing some balance sheet cushion
- Strong short-term liquidity with 4.31x current ratio
TMCI Stock Risks: Treace Medical Concepts, Inc.. Investment Risks
- Severe and deteriorating net losses (-$59.0M with -5.8% YoY decline) indicating unsustainable business model
- Negative operating cash flow (-$16.0M) and free cash flow (-$29.5M) with <5 months cash runway at current burn rate
- Critical solvency risk from minimal cash position ($10.7M) relative to long-term debt ($55.6M)
- Massive operating margin of -25.5% suggesting uncontrolled OpEx/SG&A expenses despite strong product margins
- Negative interest coverage ratio of -10.2x indicates inability to service debt from operations
Key Metrics to Watch
- Operating cash flow trend and time to cash depletion
- Operating expense as percentage of revenue and cost reduction initiatives
- Revenue growth acceleration needed to achieve breakeven operations
- Debt covenant compliance and refinancing needs
Treace Medical Concepts, Inc.. (TMCI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.31x current ratio provides a solid financial cushion.
TMCI Profit Margin, ROE & Profitability Analysis
TMCI vs Healthcare Sector: How Treace Medical Concepts, Inc.. Compares
How Treace Medical Concepts, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Treace Medical Concepts, Inc.. Stock Overvalued? TMCI Valuation Analysis 2026
Based on fundamental analysis, Treace Medical Concepts, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Treace Medical Concepts, Inc.. Balance Sheet: TMCI Debt, Cash & Liquidity
TMCI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Treace Medical Concepts, Inc..'s revenue has grown significantly by 125% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.81 indicates the company is currently unprofitable.
TMCI Revenue Growth, EPS Growth & YoY Performance
TMCI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $45.1M | -$15.4M | $-0.25 |
| Q2 2025 | $44.5M | -$15.9M | $-0.28 |
| Q1 2025 | $51.1M | -$15.9M | $-0.25 |
| Q3 2024 | $40.8M | -$12.3M | $-0.25 |
| Q2 2024 | $42.0M | -$12.3M | $-0.20 |
| Q1 2024 | $42.2M | -$13.5M | $-0.23 |
| Q3 2023 | $33.1M | -$9.0M | $-0.22 |
| Q2 2023 | $30.0M | -$9.0M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Treace Medical Concepts, Inc.. Dividends, Buybacks & Capital Allocation
TMCI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Treace Medical Concepts, Inc.. (CIK: 0001630627)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TMCI
What is the AI rating for TMCI?
Treace Medical Concepts, Inc.. (TMCI) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TMCI's key strengths?
Claude: Excellent gross margin of 79.8% indicating strong product demand and pricing power. Stagnant but not declining revenue at 1.6% YoY growth.
What are the risks of investing in TMCI?
Claude: Severe and deteriorating net losses (-$59.0M with -5.8% YoY decline) indicating unsustainable business model. Negative operating cash flow (-$16.0M) and free cash flow (-$29.5M) with <5 months cash runway at current burn rate.
What is TMCI's revenue and growth?
Treace Medical Concepts, Inc.. reported revenue of $212.7M.
Does TMCI pay dividends?
Treace Medical Concepts, Inc.. does not currently pay dividends.
Where can I find TMCI SEC filings?
Official SEC filings for Treace Medical Concepts, Inc.. (CIK: 0001630627) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TMCI's EPS?
Treace Medical Concepts, Inc.. has a diluted EPS of $-0.93.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TMCI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Treace Medical Concepts, Inc.. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TMCI stock overvalued or undervalued?
Valuation metrics for TMCI: ROE of -67.6% (sector avg: 15%), net margin of -27.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TMCI stock in 2026?
Our dual AI analysis gives Treace Medical Concepts, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TMCI's free cash flow?
Treace Medical Concepts, Inc..'s operating cash flow is $-16.0M, with capital expenditures of $13.5M. FCF margin is -13.9%.
How does TMCI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -27.7% (avg: 12%), ROE -67.6% (avg: 15%), current ratio 4.31 (avg: 2).